Skip to content
Toni Choueiri, MD· @DrChoueiri · X·· 2 days agoScore70
Body

Post-IO RCC update by @DrDanielHeng in LITESPARK-011 Ph.III:
Bel/Len vs Cabo maintained PFS benefit (14.8 vs 10.8 mo; HR 0.74).
ORR 53% vs 40%; DOR 22 vs 12 mo.
OS favored Bel/Len (33.7 vs 28.6 mo; HR 0.85) but missed significance boundary.

#ESMO26 #RCC @myESMO @OncoAlert

198 views · 6 likes · 5 reposts · 0 replies

Source: Toni Choueiri, MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.